ContractOption and Exclusive License Agreement • November 18th, 2019
Contract Type FiledNovember 18th, 2019DEBIOPHARM AND AURIGENE SIGN AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALISATION OF DEBIO 1142, A NOVEL INHIBITOR OF AN UNDISCLOSED ONCOLOGY PATHWAY